NCT01044329

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Conditions

• Branch Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	Bevacizumab	Intravitreal, 1.25 mg, 3 times, one month apart.
DRUG	Triamcinolone Acetonide	Intravitreal, 2 mg, 2 times, two months apart.

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-08-01
• Completion: 2010-12-01
• First posted: 2010-01-07
• Last updated: 2010-01-07

Locations

1 site across 1 country: Iran